Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGTX NASDAQ:CRDF NASDAQ:FRMM NASDAQ:NRSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$0.95-6.1%$1.21$0.55▼$3.83$84.58M1.751.29 million shs1.27 million shsCRDFCardiff Oncology$0.91-30.9%$1.49$0.83▼$4.56$61.40M1.441.21 million shs11.66 million shsFRMMForum Markets$6.08-10.7%$5.08$1.76▼$174.60$81.10M1.37844,256 shs248,406 shsNRSNNeuroSense Therapeutics$0.71-2.3%$0.78$0.63▼$2.10$23.22M1.58178,434 shs45,559 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics-0.98%-6.48%-16.53%-7.34%+66.94%CRDFCardiff Oncology-2.96%-2.96%-14.94%-22.94%-68.28%FRMMForum Markets+4.94%+19.30%+27.10%+219.25%+679,999,900.00%NRSNNeuroSense Therapeutics0.00%+3.09%-0.71%0.00%-63.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$0.95-6.1%$1.21$0.55▼$3.83$84.58M1.751.29 million shs1.27 million shsCRDFCardiff Oncology$0.91-30.9%$1.49$0.83▼$4.56$61.40M1.441.21 million shs11.66 million shsFRMMForum Markets$6.08-10.7%$5.08$1.76▼$174.60$81.10M1.37844,256 shs248,406 shsNRSNNeuroSense Therapeutics$0.71-2.3%$0.78$0.63▼$2.10$23.22M1.58178,434 shs45,559 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics-0.98%-6.48%-16.53%-7.34%+66.94%CRDFCardiff Oncology-2.96%-2.96%-14.94%-22.94%-68.28%FRMMForum Markets+4.94%+19.30%+27.10%+219.25%+679,999,900.00%NRSNNeuroSense Therapeutics0.00%+3.09%-0.71%0.00%-63.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGTXCognition Therapeutics 2.50Moderate Buy$3.33251.62% UpsideCRDFCardiff Oncology 2.17Hold$7.50728.73% UpsideFRMMForum Markets 2.50Moderate Buy$10.0064.61% UpsideNRSNNeuroSense Therapeutics 2.60Moderate Buy$8.501,092.15% UpsideCurrent Analyst Ratings BreakdownLatest NRSN, FRMM, CRDF, and CGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026FRMMForum Markets Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/24/2026CGTXCognition Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/22/2026CGTXCognition Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.006/3/2026CRDFCardiff Oncology Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$2.006/1/2026CRDFCardiff Oncology TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/1/2026CRDFCardiff Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/29/2026FRMMForum Markets Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/18/2026CRDFCardiff Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/15/2026FRMMForum Markets BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSpeculative Buy$5.00 ➝ $9.005/11/2026FRMMForum Markets Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$11.005/11/2026FRMMForum Markets Clear StrSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGTXCognition TherapeuticsN/AN/AN/AN/A$0.39 per shareN/ACRDFCardiff Oncology$590K104.87N/AN/A$0.67 per share1.35FRMMForum Markets$9.41M8.65N/AN/A$12.59 per share0.48NRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.05) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGTXCognition Therapeutics-$23.49M-$0.24N/AN/AN/AN/A-72.68%-53.07%8/6/2026 (Estimated)CRDFCardiff Oncology-$45.85M-$0.67N/AN/AN/A-8,527.43%-95.51%-71.47%8/4/2026 (Estimated)FRMMForum Markets-$450.52M-$36.07N/A37.97N/AN/A-242.09%-135.46%N/ANRSNNeuroSense Therapeutics-$11.12M-$0.54N/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)Latest NRSN, FRMM, CRDF, and CGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026CGTXCognition Therapeutics-$0.06N/AN/AN/A$5.00 millionN/A8/4/2026Q2 2026CRDFCardiff Oncology-$0.17N/AN/AN/A$0.06 millionN/A5/14/2026Q1 2026CRDFCardiff Oncology-$0.13-$0.18-$0.05-$0.18$0.09 million$0.04 million5/14/2026Q1 2026FRMMForum MarketsN/A-$3.64N/A-$3.58N/A$2.86 million5/7/2026Q1 2026CGTXCognition Therapeutics-$0.06-$0.05+$0.01-$0.05$4.40 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGTXCognition TherapeuticsN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/AFRMMForum MarketsN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGTXCognition TherapeuticsN/A5.925.92CRDFCardiff OncologyN/A3.273.27FRMMForum Markets0.156.196.19NRSNNeuroSense TherapeuticsN/A0.310.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGTXCognition Therapeutics43.35%CRDFCardiff Oncology16.29%FRMMForum Markets4.07%NRSNNeuroSense Therapeutics1.04%Insider OwnershipCompanyInsider OwnershipCGTXCognition Therapeutics11.11%CRDFCardiff Oncology8.50%FRMMForum Markets25.20%NRSNNeuroSense Therapeutics27.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGTXCognition Therapeutics2089.50 million79.56 millionNot OptionableCRDFCardiff Oncology2068.37 million62.56 millionOptionableFRMMForum Markets713.39 million10.02 millionN/ANRSNNeuroSense Therapeutics1032.56 million23.64 millionNot OptionableNRSN, FRMM, CRDF, and CGTX HeadlinesRecent News About These CompaniesNeurosense Therapeutics Ltd. (NRSN) Gets a Buy from Noble FinancialJuly 10, 2026 | theglobeandmail.comNeuroSense Therapeutics Ltd. Ordinary Shares (NRSN)July 8, 2026 | nasdaq.comNeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"July 6, 2026 | prnewswire.comNeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALSJune 29, 2026 | prnewswire.comNeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's DiseaseJune 25, 2026 | prnewswire.comEverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the DotsJune 22, 2026 | prnewswire.comNeuroSense Therapeutics (NASDAQ:NRSN) CEO Alon Ben-Noon Purchases 250,000 SharesJune 18, 2026 | insidertrades.comNeuroSense Granted South Korean Patent Covering PrimeC Composition for ALSJune 11, 2026 | prnewswire.comNeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel CompositionJune 9, 2026 | prnewswire.comNRSN Share News TodayMay 19, 2026 | uk.investing.comNeuroSense Secures Insider-Led $600,000 PIPE at Premium Share PriceApril 28, 2026 | tipranks.comNeuroSense Announces Pricing of Insider-Led PIPE FinancingApril 28, 2026 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Opus Genetics (IRD)April 9, 2026 | theglobeandmail.comNeuroSense Granted Brazilian Patent Covering PrimeC CompositionApril 6, 2026 | prnewswire.comNeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value RequirementsApril 3, 2026 | prnewswire.comNeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business UpdateMarch 31, 2026 | prnewswire.comNeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's ReadoutMarch 24, 2026 | prnewswire.comPrimeC New Data to Be Presented at AD/PD™ 2026 ConferenceMarch 18, 2026 | prnewswire.comNeuroSense: JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological ActivityMarch 16, 2026 | finanznachrichten.deJAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological ActivityMarch 16, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRSN, FRMM, CRDF, and CGTX Company DescriptionsCognition Therapeutics NASDAQ:CGTX$0.95 -0.06 (-6.14%) As of 03:56 PM Eastern This is a fair market value price provided by Massive. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Cardiff Oncology NASDAQ:CRDF$0.90 -0.41 (-30.92%) As of 03:56 PM Eastern This is a fair market value price provided by Massive. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Forum Markets NASDAQ:FRMM$6.08 -0.73 (-10.66%) As of 03:56 PM Eastern This is a fair market value price provided by Massive. Learn more.Forum Markets Inc is a digital asset platform modernizing capital markets through the tokenization of institutional-grade real-world assets on Ethereum. The company structures cash-generating assets on blockchain-based infrastructure to facilitate liquidity, investor access, and primary and secondary market activity. It combines traditional asset management practices with digital market infrastructure to support the origination, distribution, and trading of real-world assets.NeuroSense Therapeutics NASDAQ:NRSN$0.71 -0.02 (-2.33%) As of 03:55 PM Eastern This is a fair market value price provided by Massive. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings Why ASML’s AI Monopoly Is Still Getting Stronger Alphabet’s AI Spending Question Looms Over Q2 Earnings CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks 2 Quantum Stocks That Could Challenge IonQ’s Leadership 3 Small-Cap Stocks Trading Under $10 With Room to Run Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
